

Prof. Dr. Taner KORKMAZ

Kişisel Bilgiler

E-posta: taner.korkmaz@acibadem.edu.tr

Web: <https://avesis.acibadem.edu.tr/taner.korkmaz>

Uluslararası Araştırmacı ID'leri

ORCID: 0000-0003-4292-0545

Yoksis Araştırmacı ID: 172312

SCI, SSCI ve AHCI İndekslerine Giren Dergilerde Yayınlanan Makaleler

- I. **Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study**
Hızal M., BİLGİN B., Paksoy N., Kilickap S., Atci M. M., Kahraman S., Keskinilic M., Bilgetekin I., Ayhan M., Tural D., et al.
FUTURE ONCOLOGY, sa.23, ss.2573-2582, 2022 (SCI-Expanded)
- II. **Pretreatment PET/CT Standardized Uptake Values Play a Role in Predicting Response to Treatment and Survival in Patients with Small Cell Lung Cancer**
Dinc N. S., Aydın K., Odabas H., Ercelep O., Tufan G., ŞEKER M., Yasar N., Aydın D., Yuksel S., Mert A., et al.
ONCOLOGY RESEARCH AND TREATMENT, cilt.39, sa.3, ss.130-134, 2016 (SCI-Expanded)
- III. **Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis**
Genestreti G., Tiseo M., Kenmotsu H., Kazushige W., Di Battista M., Cavallo G., Carloni F., Bongiovanni A., Burgio M. A., Casanova C., et al.
CLINICAL LUNG CANCER, cilt.16, sa.6, 2015 (SCI-Expanded)
- IV. **Clinical Outcome of Turkish Metastatic Breast Cancer Patients with Currently Available Treatment Modalities - Single Center Experience**
Cabuk D., BAŞARAN G., Teomete M., Dane F., Korkmaz T., Seber S., Telli F., Yumuk P. F., Turhal S.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, cilt.15, sa.1, ss.117-122, 2014 (SCI-Expanded)
- V. **Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis**
Korkmaz T., Seber S., KEFELİ U., Sari E., Canhoroz M., Oven B., Yildirim E., Yasar N., Aydın D., Balvan O., et al.
CLINICAL & TRANSLATIONAL ONCOLOGY, cilt.15, sa.7, ss.535-540, 2013 (SCI-Expanded)
- VI. **Serum thymidine kinase 1 levels correlates with FDG uptake and prognosis in patients with non small cell lung cancer**
Korkmaz T., Seber S., Okutur K., BAŞARAN G., Yumuk F., Dane F., ÖNEŞ T., Polat O., Madenci O. C., Demir G., et al.
BIOMARKERS, cilt.18, sa.1, ss.88-94, 2013 (SCI-Expanded)
- VII. **Clinical outcome of breast cancer patients with N3a (≥ 10 positive lymph nodes) disease: has it changed over years?**
BAŞARAN G., Devrim C., Çağlar H. B., GÜLLÜOĞLU M. B., KAYA H., Seber S., Korkmaz T., Telli F., Kocak M., Dane F., et al.
MEDICAL ONCOLOGY, cilt.28, sa.3, ss.726-732, 2011 (SCI-Expanded)

Diğer Dergilerde Yayınlanan Makaleler

- I. **Prevalence of K-Ras mutations in hepatocellular carcinoma: A Turkish Oncology Group pilot study**
Turhal N. S., SAVAŞ B., COŞKUN Ö., Bas E., Karabulut B., Nart D., KORKMAZ T., Yavuzer D., Demir G., Dogusoy G., et al.
MOLECULAR AND CLINICAL ONCOLOGY, sa.6, ss.1275-1279, 2015 (ESCI)

Metrikler

Yayın: 43

Atıf (WoS): 251

Atıf (Scopus): 217

H-İndeks (WoS): 10

H-İndeks (Scopus): 9

Kongre ve Sempozyum Katılımı Faaliyetleri

Hedef KANSER , Moderatör, Girne, Kıbrıs (Kkct), 2022

8. Türk Tıbbi Onkoloji Kongresi , Davetli Konuşmacı, Antalya, Türkiye, 2021